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OBJECTIVES: Incidence of unintended pregnancy (UP) is a prominent public health
issue and elicits substantial health system costs. The objective of the current anal-
ysis was to estimate the direct cost of UP to the National Health Service (NHS) and
the proportion of UP costs attributable to poor adherence in the United Kingdom
(UK). The cost implications of increased long acting reversible contraception (LARC)
uptake were also explored. METHODS: An economic model evaluating costs and
outcomes over an averaged one year period of contraceptive usage was con-
structed. Model inputs were derived from published literature and national survey
data collected by the Office of National Statistics. Exploratory analyses were con-
ducted to investigate the impact of women aged 20-29 years switching to LARC
methods from existing contraceptive usage. Cost-neutrality analysis was also per-
formed whereby the minimum duration of LARC usage required to achieve a net
cost impact of zero post-switch was assessed. RESULTS: Over 400,000 UPs occur
annually in the UK at a rate of 34 per 1,000 women. Direct medical costs were
estimated to be £382 million annually. Poor adherence accounted for 67% of all UPs,
pertaining to costs of £256 million. In women aged 20-29 years, an estimated
213,794 UPs occurred at a cost of £184 million, 64% of which resulted from imperfect
adherence. Switching analyses demonstrated substantial cost savings of £12.5 mil-
lion in women aged 20-29, when 10% switched from oral contraceptives (OCs) to
LARC. The duration of LARC usage required to attain cost neutrality for patients
switching from OCs was 1.65 years. CONCLUSIONS: The vast proportion of UPs and
associated costs in the UK are attributable to poor contraceptive adherence. In-
creased uptake of LARC methods in young women may generate significant cost
savings to UK health care payers in under 2 years.
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The economic burden of early-onset neonatal sepsis (EONS) is currently uncertain
in Russia. OBJECTIVES: To evaluate economic burden of EONS and mortality in the
Russian Federation, including both direct and indirect costs. METHODS: Chosen
methodology was based on the analysis of the sample of medical records from
neonatal intensive care units (NICUs). Neonates (n79) were classified according to
gestational age (GA). Direct costs were calculated based on the data about resource
consumption in real prectice. Indirect costs included underproduced contribution
to GDP due to premature death and morbidity, resulting from disease, welfare and
care payments, comprising disability support pensions. RESULTS: Mean cost of
hospitalization to NICU (direct costs) per infant with EONS is estimated as € 9,092.
Mean direct costs for hospitalization per extremely-low-birth-weight (ELBW) in-
fant are twice higher in comparison with mean direct costs per infant with GA 30
weeks of gestation (€ 21,056 per ELBW infant and € 11,938 per infant with GA 30
weeks of gestation). Total underproduced contribution to GDP is estimated as €
152,254 (87% of total costs) per infant with EONS, welfare and care payments,
comprising disability support pensions - € 14,721 (8%) per infant. Thus indirect
costs account for 95% of expenditure. Total costs associated with EONS are esti-
mated as € 176,067 per infant. CONCLUSIONS: Improvement of treatment of EONS
may play the crucial socio-economic role since it could significantly reduce the
economic burden of the disease for the Russian Federation.
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OBJECTIVES: To estimate the costs of unintended pregnancies (UP) over one year
within the Russian health care system. METHODS: We calculated direct medical
costs of a UP for women aged 15-44 per 5-year age groups (average per woman and
per age group) as sum of the costs of pregnancy outcomes (live birth, termination,
foetal loss, ectopic pregnancy) multiplied by the proportions of each pregnancy
outcome that occurred following an UP. The costs of hospital and outpatient ser-
vices for each outcome were calculated on the basis of information on typical
practice provided in expert panel interviews, rates of pregnancy complications
from federal statistics and reimbursement rates for medical services in obligatory
medical insurance in Moscow region, adjusted for the proportion of medical ex-
penditures covered by public budgets. The costs of live births were adjusted for
mistimed pregnancies, based on literature data on their proportion for age groups.
The numbers of UP were assessed using data from federal statistics on overall
pregnancy outcomes and literature data on the proportion of these outcomes due
to unintended pregnancies only. Based on the derived numbers we estimated the
distribution of UP outcomes for each age group. RESULTS: The average cost of UP
per woman varied from 12 635 RUR (€309,68) for age group 15-19 to 17 630 RUR
(€432,12) for age group 30-34. There are estimated to be annually 1 705 591 unin-
tended pregnancies occurring in Russia, with direct medical cost amounting to
approximately 26,4 billion RUR (€ 647,0 mln) annually. The highest costs are attrib-
uted to age groups 20-24 and 25-29, together accounting for 54% of overall cost
burden of UP. CONCLUSIONS: The analysis has demonstrated that in Russia UPs
elicit substantial health system costs, with the major part attributed to women
aged 20-29.
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OBJECTIVES: Endometriosis is a condition with an estimated prevalence of 10%
among women of fertile age and with a varying impact on the affected women’s
quality of life and health care consumption. The purpose of this study was to
describe to what extent affected women consume health care resources and incur
indirect costs in Sweden. METHODS: A postal survey consisting of 88 questions
concerning health care consumption, occupation, absenteeism and quality of life
was sent to 800 women recruited from The Endometriosis Association, Sweden
(n400) and from five gynecology departments at five Swedish hospitals (n400).
Descriptive statistics were performed, and direct and indirect costs were calculated
from the data. RESULTS: Women with endometriosis on average have direct costs
for primary care visits, specialist visits, hospitalization and surgery corresponding
to 51 000 SEK (5 600 Euro) per person per year. This is double the cost of care for the
general population. Indirect costs for absenteeism and lower efficiency at work
amount to 40 000 SEK (4 500 Euro) per person per year, while informal care amounts
to 2 000 SEK (200 Euro) per person per year. Women with endometriosis qualify
more frequently for free medical care and pharmaceuticals under the Swedish
benefits systems than do the general population. CONCLUSIONS: Women with
endometriosis consume more health care resources and medication than the gen-
eral population and the reported productivity losses entail a significant cost for
patients and society. Earlier diagnosis could contribute to lowering the resource
consumption, as could improved treatment efforts and support from health care
providers and society in large.
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OBJECTIVES: To investigate the prescribing cost of products classified as enzymes
in a South African private health care insurance claims database over a two-year
period. METHODS: A medical claims database for 2010 and 2011 of approximately
4.5 million records was analysed retrospectively. All products classified as en-
zymes under the MIMS classification system were extracted for analysis. RESULTS:
Enzymes constituted a very small percentage of medical insurance claims in this
study (only 0.02% of approximately 4.5 million claims for products and procedures),
yet they were relatively expensive. Five different enzyme products were pre-
scribed. A total of 906 products (525 in 2010 and 381 in 2011) were prescribed at a
cost of R1956948.76 (average cost of R2159.99; SDR9929.54) over the two years.
Hyaluronidase was the most frequently prescribed (60.04% of all enzyme products),
followed by pancreatin-containing products (34.66%). The average cost per hyal-
uronidase prescription paid by the medical aids was R280.54. The Single Exit Price
(SEP) (unit price) of hyaluronidase on 12 January 2012 was R283.40. Other enzymes
prescribed were imiglucerase, alteplase and tenecteplase. Imiglucerase was overall
the most expensive (a cost of R58103.26 for the 200 units/5 ml vials and R62470.48
for the 400 units/5 ml vials prescribed). The average cost of alteplase (recombinant
human human tissue type plasminogen activator or r-tPA) was R6572.60 per pre-
scription. The amount claimed per tenecteplase injection was R11905.72 (8000
units) and R13091.24 (10000 units), respectively. Streptokinase, regarded as the
most affordable antithrombotic enzyme, was not prescribed. Of the 579 patients
who received one or more prescriptions for these products, 64.59% were between
40 and 69 years of age.CONCLUSIONS:These products are relatively expensive and
warrant further pharmacoeconomic studies. The importance of studies which in-
clude diagnoses and clinical parameters cannot be overemphasised.
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OBJECTIVES: To evaluate the incidence of Herpes Zoster (HZ) and its complications
in Israel, as well as related resource-utilization, among the general population and
among immunocompromised patients. METHODS: A retrospective analysis of the
Maccabi Healthcare Services (MHS) database for all 2 million members of all ages
for the years 2006-2010. Patients were identified using ICD-9 codes and MHS’s
internal codes. Demographic, clinical and billing data were recorded. RESULTS:
Annual incidence of HZ was 3.7 per 1,000. Incidence increased with age, with a peak
in the 75-84 years age group (11.95 per 1,000 per year), and was higher in females
than in males. Incidence of Post Herpetic Neuralgia (PHN), the most significant
complication of HZ, also increased with age, reaching 1.9 per 1,000 per year among
85 years old. Fourteen percent of the elderly HZ patients (65 years) developed
PHN. HZ incidence was higher among immunocompromised patients than in the
general population, reaching 16.8 and 15.9 per 1000 of the elderly in each group,
respectively. Seventeen percent of elderly HZ patients developed PHN. HZ patients
consumed more health care resources than the general population of the same age
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and gender, including physician visits, pain-clinic visits, neurology-clinic visits,
and ED visits. In the 75-84 years age group, frequency of utilization was higher by
22%, 39%, 45% and 48% for these health care resources, respectively.
CONCLUSIONS: Epidemiology of HZ in Israel is similar to that reported for other
countries. This illness presents a burden on the elderly population and is related
with increased resource utilization.
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OBJECTIVES: To quantify the economic effects of an in-vitro-fertilization (IVF) born
persons in terms of productivity gains and net tax revenues for the state in Greece.
METHODS:A mathematical model was developed to assess the lifetime productiv-
ity and transactions between an individual and the governmental agencies. The
model distinguishes amongst three periods in economic life cycle: 1) early life,
when the government primarily contributes resources through child tax credits,
health care, and educational expenses; 2) employment, when individuals begin
returning resources through taxes; and 3) retirement, when the government ex-
pends additional resources on Social Security and old-age programs. Cost of life
birth with IVF was based on a modification of a previous published model devel-
oped by the authors. All outcomes were discounted at a 3% discounting rate. The
data inputs, namely the economic or demographic variables, were derived from
National Statistical Secretariat of Greece and other relevant sources. To deal with
uncertainty, bias corrected uncertainty intervals (UI) was calculated based on 5000
Monte Carlo simulations. In addition, to examine the robustness of our results,
other one-way sensitivity analyses were also employed. RESULTS: The cost of IVF
per birth was estimated at €17,078 (95%UI: €16,350-€17,805). The average projected
income generated by an individual throughout his productive life, was €667,651
(95%UI: €538,897-€762,862). In addition, his life tax contribution was estimated at
€200,295 (95%UI: €168,669-228,670), while the discounted governmental expenses
for elderly and underage individuals were at €36,570 (95%UI: €33,614-€40,463).
Hence, the net present value of IVF was €163,726 (95%UI: €124,533-€192,215) repre-
senting a 547% net return on investment. Results remained constant under various
assumptions for the main model parameters. CONCLUSIONS: State-funded IVF
represents good value for money in the Greek setting, as it has positive tax benefits
for the government, notwithstanding its beneficial psychological effect for infertil-
ity couples and the overall productivity gains.
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Infections are a major contributor to neonatal mortality and morbidity levels all
over the world. OBJECTIVES: To assess clinical efficacy and cost-effectiveness of
additional immunotherapy in neonates with severe infections in neonatal inten-
sive care unit (NICU). METHODS: We observed 375 neonates (gestational age (GA)
25-41 weeks) with severe early-onset infections in NICU. Fifty-two neonates with
hypogammaglobulinemia were treated with normal human immunoglobulin
(NHI), 85 newborn infants with lymphopenia were treated with human interleukin
2 (HI2), 94 neonates with low mitogen-induced interferon- production treated
with interferon-2b. A total of 144 were under standard treatment without addi-
tional immunotherapy. RESULTS: Administration of NHI resulted in reduction of
NICU length of stay and mortality level in cases of septic shock - 7.1% [0.2%; 34%] vs
40% in a similar group without immunosubstitutive therapy (p0.05). Administra-
tion of interferon-2b reduces hospital length of stay and mortality rates (g0.009,
OR  0.21 [0.05; 0.67], RR  0.26 [0.07; 0.69], NNT8 [4; 29]). Administration of HI2
reduces NICU length of stay and mortality rates from severe infection (g0.047;
OR0.36 [0.13; 0.98]; RR0.41 [0.17; 0.98]; NNT9 [4; 214]). Administration of immu-
notherapy in early-onset neonatal infections leads to substantial cost savings up to
€ 168,896 per patient in case of NHI treatment, € 60,910 per patient in case of HI2
treatment and € 69, 247 per patient in case of interferon-2b administration.
CONCLUSIONS: Additional immunotherapy in early-onset neonatal infections is a
cost-effective intervention that allows to reduce mortality rates and save money.
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OBJECTIVES: To investigate the cost effectiveness of intermittent treatment of
PMDD (premenstrual dysphoric disorder) with Premalex (escitalopram) 20 mg com-
pared with sertraline 50-100 mg based upon the Clinical Global Impressions – Se-
verity (CGI-S), from a societal perspective. METHODS: We identified one ran-
domised placebo controlled trial with sertraline and one with Premalex, reporting
the CGI-S as an outcome. Using placebo, the CGI-S was used to make an indirect
effect comparison between Premalex and sertraline. The CGI-S was translated into
QALY weights, through the proportion of time spent with a high degree of the
anxiety/depression in the EQ-5D. Costs of health care visits were estimated using a
local treatment pattern survey among GPs and gynaecologists. Official drug prices
were used. A Premalex dose of 15 mg, the average of 10 and 20 mg, was assumed as
it is stated in the SPC text that many of the patients will benefit from 10 mg. 37-75%
lower drug costs were used in years 2-3 due to expected generic competition.
Indirect costs were estimated using a published international study of the effect of
PMDD on sick leave and productivity. A societal perspective was taken over a 3-year
time frame. RESULTS:During the first year, Premalex treatment increased drug costs
(SEK 1599), partly offset by indirect costs saving (SEK 1413), resulting in a total cost of
SEK 186, compared to sertraline. An estimated gain of 0.0044 QALYs with Premalex
compared to sertraline gave an incremental cost per QALY gained of SEK 42200 (EUR
4700). In the next 2 years, drug costs were more than offset by indirect costs saving,
leading to an overall gain of 0.0132 QALYs and a savings of SEK 1600 per three years
with Premalex compared to sertraline.CONCLUSIONS: Treatment of PMDD with Pre-
malex is cost effective compared to sertraline, from a societal perspective.
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OBJECTIVES:A very recent Meta-Analysis shows that the addition of Omega-3 fatty
acid in standard Total Parenteral Nutrition (TPN) is associated with reductions in
infection rate, ICU, and overall lengths of stay (LOSs) for both Intensive Care Unit
(ICU) and elective surgery patients. Aim of this study is the CE analysis of its use in
these patient populations, as compared to standard lipid emulsions. METHODS:
Within a Discrete Event Simulation (DES) scheme, a patient-level simulation model
was developed, with the inclusion of baseline outcomes rates from the Italian ICU
patient population and from published literature; comparative efficacy data for
standard and Omega-3 fatty acids-based regimens from the meta-analysis of pub-
lished randomized clinical trials (conducted on 23 studies with a total of 1502
patients), and country-specific cost data. Clinical outcomes included in the model
are death rates, nosocomial infection rates, and ICU/hospital LOSs. Costs are re-
ferred to Italian, French German and UK health care systems. Probabilistic and
deterministic sensitivity analyses are undertaken to test results’ reliability.
RESULTS:Omega-3 fat emulsions emerged as more effective on average than stan-
dard TPN both in ICU and in non-ICU patients: in all the four national contexts here
considered, reduced mortality rates, infection rates, and overall LOSs yield a lower
total cost per patient. Treatment costs are completely offset by the reduction in
hospital stay costs and antibiotic costs. Sensitivity analyses confirmed the robust-
ness of these findings. CONCLUSIONS: These results indicate that the addition of
Omega-3 to standard TPN is expected to improve clinical outcomes and concur-
rently give a saving for Italian, French, German and UK hospitals.
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OBJECTIVES: LNG-IUS 12 is a novel intrauterine contraceptive system for up to 3
years use with an average in vitro release rate of 12g of levonorgestrel per day.
This study was conducted to estimate the relative cost-effectiveness of LNG-IUS 12
versus short-acting reversible contraception (SARC) in the United States from a
third-party payer’s perspective. METHODS: A Markov model was constructed to
compare the effectiveness and costs of LNG-IUS 12 and SARC over a 3-year period
in a cohort of 1000 women aged 20 to 29 years, the age group in which most
unplanned pregnancies occur. SARC methods comprise contraceptives commonly
used by this age cohort, including oral contraceptives, the ring, the patch and
injections. Primary health states included initial/continued use of contraceptive
method and method failure (unplanned pregnancies). The impact of switching
methods was also incorporated into the model and tested through sensitivity anal-
ysis. Estimates for probabilities of failure and discontinuation, resource utilization
and costs were derived from a comprehensive literature review, average wholesale
drug prices and the 2012 Medicare Reimbursement Fee Schedule, respectively. Cost
and effectiveness metrics for SARC were calculated as weighted averages using
distribution of use data for SARC. One-way sensitivity analyses were performed on
all key variables. RESULTS: LNG-IUS 12 dominated SARC in women aged 20 to 29
years, resulting in fewer unplanned pregnancies (9.86 vs. 238.75) and lower total
costs ($930,187USD vs. $1,528,163USD, a 39% saving) over 3 years. The cost of con-
traception and number of unplanned pregnancies associated with SARC were key
model drivers. Results were insensitive to variation in key input values during
one-way sensitivity analyses. CONCLUSIONS: From a third-party payer perspec-
tive, LNG-IUS 12 is a more cost-effective contraceptive option than SARC. Addi-
tional analysis of discontinuation patterns and planned pregnancy events within
future model extensions will help to further reflect real-life utilization pattern.
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